Phaseline

Companies › Oryzon Genomics

Oryzon Genomics: clinical trials, targets and expected readouts

1 active drug program in 5 registered trials: 4 Phase 1, 1 Phase 2; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Iadademstat
LSD1 inhibitor
KDM1APhase 1Acute Myeloid Leukemia, in Relapse; Accelerated Phase Myeloproliferative Neoplasm; Acute Myeloid Leukemia; Extensive Stage Lung Small Cell Carcinoma …Dec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05546580IadademstatPhase 1Acute Myeloid Leukemia, in RelapseOncologyDec 2026
NCT06357182IadademstatPhase 1Acute Myeloid LeukemiaOncologyMar 2027
NCT06661915IadademstatPhase 2Accelerated Phase Myeloproliferative NeoplasmOncologyDec 2027
NCT06287775IadademstatPhase 1Extensive Stage Lung Small Cell CarcinomaOncologyJul 2029
NCT07113691IadademstatPhase 1Extensive Stage Small Cell Lung Cancer (ES-SCLC)OncologyJan 2030

Targets

KDM1A (1)

Companies with the same targets

Merck & Co. (MSD) Daiichi Sankyo

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.